All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

A single-center experience with magnetically levitated left ventricular assist device for treatment of end-stage heart failure

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F20%3A00080688" target="_blank" >RIV/00023001:_____/20:00080688 - isvavai.cz</a>

  • Result on the web

    <a href="https://www.cesurg.ru/en/jarticles_cesurg/426.html?SSr=190134622813ffffffff27c__07e502100d1311-72ec" target="_blank" >https://www.cesurg.ru/en/jarticles_cesurg/426.html?SSr=190134622813ffffffff27c__07e502100d1311-72ec</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.33029/2308-1198-2020-8-3-7-16" target="_blank" >10.33029/2308-1198-2020-8-3-7-16</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    A single-center experience with magnetically levitated left ventricular assist device for treatment of end-stage heart failure

  • Original language description

    Background. The HeartMate 3 Left Ventricular Assist System is a recent compact fully magnetically levitated centrifugal-flow continuous ventricular assist device engineered to enhance hemocompatibility. The aim of this study was to evaluate clinical characteristics, adverse event rates, survival and outcomes of patients supported with HeartMate 3 LVAS. Material and methods. We retrospectively reviewed a cohort of consecutive 150 patients implanted with HeartMate 3 LVAS at a single institution between April 2016 and June 2020. Results. The study comprised of 150 patients (125 male; 83%) aged 57.2±11.9 years, with majority in INTERMACS profile 3 (n=65; 43.3%). During 4-year follow-up 32 patients were transplanted, 37 had died, 78 are ongoing and in 3 (2%) patients had a myocardial recovery. The actuarial survival after device implantation was 77.6, 74.6, 74.6 and 69.9% at 12, 24, 36 and 48 months respectively. 46 (31%) patients were implanted temporary RVAD. Other most frequent adverse events included infections (74 patients; 49.3%), major bleeding (38; 25.3%) or neurological dysfunction (16; 10.6%). Conclusion. We have observed survival rates comparable with international registries using the HeartMate 3 LVAS for long-term circulatory support. The results of the study confirm high reliability of the system, enhanced hemocompatibility and improved adverse event rates, nevertheless, some complications remain a concern. © 2020 GEOTAR Media. All rights reserved.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database

  • CEP classification

  • OECD FORD branch

    30212 - Surgery

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Clinical and experimental surgery

  • ISSN

    2308-1198

  • e-ISSN

  • Volume of the periodical

    8

  • Issue of the periodical within the volume

    3

  • Country of publishing house

    RU - RUSSIAN FEDERATION

  • Number of pages

    10

  • Pages from-to

    7-16

  • UT code for WoS article

  • EID of the result in the Scopus database

    2-s2.0-85098684874